Causaly today announced new scientific AI agents that provide research teams with the industry's most comprehensive ...

On the same day, Novo Nordisk's stock price fell by 1.34%, with a market capitalization of approximately 2 trillion kroner (approximately 436 trillion won). SAP logo. /Courtesy of Reuters SAP is a ...

St. Christopher's Hospital for Children, a nationally recognized leader in pediatric health care, medical training and research, today kicked off a celebration of its 150th anniversary. The milestone, ...

A steady stream of buses, each adorned with the logo of Boao Forum for Asia, flows through the bustling streets, packed with government officials, industry representatives and journalists from around ...

Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus. A clinical trial ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Novo Nordisk's (NYSE: NVO) is famous and celebrated for its cutting-edge obesity medication. But on Thursday, its stock felt ...